User:Saravo1/sandbox

hi

When examining Embroynal Rhabdomyosarcoma tumors vs. Alveolar Rhabdomyosarcoma tumors, a 2013 study had discovered that there were more rates of mutation in ERMS tumors.

Risk Factors associated with possible increased Embryonal Rhabdomyosarcoma include cigarette smoking, older age of mother, x-ray exposure, and maternal drug use.

In order to create an optimal treatment plan for the patient, therapy is often based upon risk stratification (low, intermediate, or high risk) based off of patient's disease stage, size of tumor, surgery resection, age at diagnosis, and site of tumor.

The study had use whole genome sequencing to sequence the DNA from 16 RMS tumors and found that RAS pathway mutations tend to be more associated with intermediate and high risk embryonal Rhabdomyosarcoma.[1]

Additionally, Embryonal Rhabdomyosarcoma tends to be more common in males versus females, with an occurence of 1.4:1.[1]

Treatment for Embryonal rhabdomyosarcoma involves the use of combination therapy consisting of chemotherapy, surgery, and/or radiation therapy. In order to create an optimal treatment plan for the patient, therapy is often based upon risk stratification (low, intermediate, or high risk) based off of patient's disease stage, size of tumor, surgery resection, age at diagnosis, and site of tumor. In the US, a combination of Vincristine, Dactinomycin, and cyclophosphamide are often the chemotherapeutics used to treat rhabdomyosarcoma. Radiation therapy continues to be an integral component of rhabdomyosarcoma treatment, however, the long-term safety and treatment related complications remain a concern.

In individuals with localized rhabdomyosarcoma, surgery and/or radiation therapy are primarily use to eliminate the tumor. Localized rhabdomyosarcoma can typically be treated successfully with the current standard of care.

In individuals with metastatic rhabdomyosarcoma, combination therapy is not able to treat specific sites such as bone marrow or the lungs. Treatment for metastatic rhabdomyosarcoma has not changed over the last 3 decades and 5-year survival outcomes in those with high-risk rhabdomyosarcoma remain less than 40%. In a European study on 174 adolescents with metastatic rhabdomyosarcoma, high dose chemotherapy compared to standard chemotherapy did not show a statistical difference in 5 year overall survival rates. In fact, those who received the high dose chemotherapy had experienced an increase in adverse events such as myelosuppression, peripheral neuropathy and/or required a dose reduction. In individuals with more resistant rhabdomyosarcoma, more targeted therapies and immunotherapies have been of interest to gain better survival outcomes and reduce toxicities and treatment resistance.

Peer Review for article- 1) The groups edits first start off with an introduction to what follicular atresia is and the introduction gives a good intro and short summary. I noticed in the first paragraph there was not much citations for each piece of info. I feel as though the first of the page was a bit hard to comprehend with the "thus..." and perhaps a easier to understand short sentence may suffice. The end summary sentence does a great job of summarizing the paragraph and was short and concise without compromising quality. In the mechanism part, I think the paragraph part of the 5 ligand receptors could be better organized and maybe utilize smaller bullet points to organize it. The menopause portion is a bit placed randomly and a suggestion would be figuring out how to merge it with related diseases. The group's edits do substantially improve the article and helps to elucidate follicular atresia.

2) Yes, I think that the group has achieved its overall goals for improvements. Everything in article in on topic and relevant to follicular atresia. The article remains neutral and is not at all biased or convincing. The sections of the article remain pretty equal. There tended to be more info on the related disease, likely because that there was more info on that topic and it is relevant. I think the group can work to elucidate some of the jargon and to better organize the article.